Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Non-Current Debt (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Non-Current Debt data on record, last reported at $286.3 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 1.43% year-over-year to $286.3 million; the TTM value through Dec 2025 reached $286.3 million, down 1.43%, while the annual FY2025 figure was $286.3 million, 1.43% down from the prior year.
  • Non-Current Debt reached $286.3 million in Q4 2025 per MRVI's latest filing, roughly flat from $287.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $744.3 million in Q3 2021 and bottomed at $286.3 million in Q4 2025.
  • Average Non-Current Debt over 5 years is $510.2 million, with a median of $519.8 million recorded in 2021.
  • Peak YoY movement for Non-Current Debt: soared 36.76% in 2022, then tumbled 44.34% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $713.5 million in 2021, then dropped by 26.84% to $522.0 million in 2022, then fell by 0.63% to $518.7 million in 2023, then crashed by 44.0% to $290.5 million in 2024, then decreased by 1.43% to $286.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $286.3 million in Q4 2025, $287.4 million in Q3 2025, and $288.4 million in Q2 2025.